Pomalidomide in lenalidomide-refractory multiple myeloma and carfilzomib in refractory and newly diagnosed multiple myeloma
Pomalidomide and carfilzomib represent active and well-tolerated new options in combination regimens.
April 1, 2011|The Journal of Community and Supportive Oncology
Author and Disclosure Information
At the time of reporting, 23 patients continued on treatment, with 20 having no need for dose modifications. After a median of 4 months of treatment (range, 1−8 months), the preliminary response rate in 19 evaluable patients completing at least 1 cycle was 100% with at least a partial response, including 63% with a very good partial response and 37% with a complete response or near-complete response. Partial responses were observed in 17 of 19 patients after 1 cycle, with responses improving in all patients with continuing treatment. Seven patients had proceeded to stem cell collection using growth factors only after a median of 4 cycles, and all resumed study treatment after stem cell collection. No disease progression had been observed in any of the evaluable patients, and all remained alive.
References
1. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010;24:1934−1939.
2. Siegel DSD, Martin T, Wang M, et al. Results of PX-171-003-A1, an open-label, single-arm, phase 2 study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). Blood 2010;116:985.
3. Jakubowiak AJ, Dytfeld D, Jagannath S, et al. Carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma: initial results of phase I/II MMRC trial. Blood 2010;116:862.
4. Singhal SB, Siegel DSD, Martin T, et al. Pooled safety analysis from phase 1 and 2 studies of carfilzomib (CFZ) in patients with relapsed and/or refractory multiple myeloma (MM). Blood 2010;116:1954.
